Dupixent retakes TV ad spending crown but overall outlay for the top 10 remains low
Dupixent retakes TV ad spending crown but overall outlay for [...]
‘Who wants to make money?’ Court documents outline wild fraud scheme targeting Gilead HIV meds
‘Who wants to make money?’ Court documents outline wild fraud [...]
Novartis halts US production of radioligand cancer therapies, citing potential quality issues
Novartis halts US production of radioligand cancer therapies, citing potential [...]
Intercept sells Ocaliva rights outside the US after NASH development woes
Intercept sells Ocaliva rights outside the US after NASH development [...]
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if [...]
Takeda spinout Phathom clinches FDA twin nods for GI infection combos—plus timely capital infusion
Takeda spinout Phathom clinches FDA twin nods for GI infection [...]
Amarin, after 33% revenue decline, aims to ‘stabilize’ US sales and grow in Europe
Amarin, after 33% revenue decline, aims to ‘stabilize’ US sales [...]
Bayer’s Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use
Bayer’s Nubeqa one step closer to blockbuster status thanks to [...]
Teva settlement prevents Lupin from launching its Austedo generic until 2033
Teva settlement prevents Lupin from launching its Austedo generic until [...]
With FDA approval, Supernus’ Qelbree is the first nonstimulant ADHD med for adults in 2 decades
With FDA approval, Supernus’ Qelbree is the first nonstimulant ADHD [...]